International consensus for the treatment of autoimmune pancreatitis

Kazuichi Okazaki, Suresh T Chari, Luca Frulloni, Markus M. Lerch, Terumi Kamisawa, Shigeyuki Kawa, Myung Hwan Kim, Philippe Lévy, Atsushi Masamune, George Webster, Tooru Shimosegawa

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background and aims: The International Consensus Diagnostic Criteria (ICDC) for AIP has proposed two distinctive type of AIP, type 1 and type 2, and enabled us first to differentiate two types of AIP each other. By initial steroid treatment for induction of remission, remission can be successfully induced in almost all subjects with type 1 and type 2 AIP. As relapse rate in type 1 AIP is significantly higher than in type 2 AIP, there has been ongoing debate on how to treat effectively relapse of type 1 AIP. Methods: By a modified Delphi approach, a panel of international experts has proposed an international consensus on the treatment of AIP after intense discussion and deliberation during an international consensus symposium of the International Association of Pancreatology (IAP) 2016. Results: Individual statements for nine clinical questions with recommendation levels and the therapeutic strategy have been proposed. Conclusion: The recommendations are based on the available evidence, and eastern and western experts' opinions to find standard treatment of AIP worldwide. These recommendations can be tailored according to the local expertise and context in the management of individual patients.

Original languageEnglish (US)
JournalPancreatology
DOIs
StateAccepted/In press - Sep 7 2016

Fingerprint

Pancreatitis
Remission Induction
Recurrence
Expert Testimony
Therapeutics
Steroids

Keywords

  • Autoimmune pancreatitis
  • Immunomodulatory
  • Rituximab
  • Steroid
  • Treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Okazaki, K., Chari, S. T., Frulloni, L., Lerch, M. M., Kamisawa, T., Kawa, S., ... Shimosegawa, T. (Accepted/In press). International consensus for the treatment of autoimmune pancreatitis. Pancreatology. https://doi.org/10.1016/j.pan.2016.12.003

International consensus for the treatment of autoimmune pancreatitis. / Okazaki, Kazuichi; Chari, Suresh T; Frulloni, Luca; Lerch, Markus M.; Kamisawa, Terumi; Kawa, Shigeyuki; Kim, Myung Hwan; Lévy, Philippe; Masamune, Atsushi; Webster, George; Shimosegawa, Tooru.

In: Pancreatology, 07.09.2016.

Research output: Contribution to journalArticle

Okazaki, K, Chari, ST, Frulloni, L, Lerch, MM, Kamisawa, T, Kawa, S, Kim, MH, Lévy, P, Masamune, A, Webster, G & Shimosegawa, T 2016, 'International consensus for the treatment of autoimmune pancreatitis', Pancreatology. https://doi.org/10.1016/j.pan.2016.12.003
Okazaki, Kazuichi ; Chari, Suresh T ; Frulloni, Luca ; Lerch, Markus M. ; Kamisawa, Terumi ; Kawa, Shigeyuki ; Kim, Myung Hwan ; Lévy, Philippe ; Masamune, Atsushi ; Webster, George ; Shimosegawa, Tooru. / International consensus for the treatment of autoimmune pancreatitis. In: Pancreatology. 2016.
@article{4fd85803d3df4ae3b2dcb5252c6eaef1,
title = "International consensus for the treatment of autoimmune pancreatitis",
abstract = "Background and aims: The International Consensus Diagnostic Criteria (ICDC) for AIP has proposed two distinctive type of AIP, type 1 and type 2, and enabled us first to differentiate two types of AIP each other. By initial steroid treatment for induction of remission, remission can be successfully induced in almost all subjects with type 1 and type 2 AIP. As relapse rate in type 1 AIP is significantly higher than in type 2 AIP, there has been ongoing debate on how to treat effectively relapse of type 1 AIP. Methods: By a modified Delphi approach, a panel of international experts has proposed an international consensus on the treatment of AIP after intense discussion and deliberation during an international consensus symposium of the International Association of Pancreatology (IAP) 2016. Results: Individual statements for nine clinical questions with recommendation levels and the therapeutic strategy have been proposed. Conclusion: The recommendations are based on the available evidence, and eastern and western experts' opinions to find standard treatment of AIP worldwide. These recommendations can be tailored according to the local expertise and context in the management of individual patients.",
keywords = "Autoimmune pancreatitis, Immunomodulatory, Rituximab, Steroid, Treatment",
author = "Kazuichi Okazaki and Chari, {Suresh T} and Luca Frulloni and Lerch, {Markus M.} and Terumi Kamisawa and Shigeyuki Kawa and Kim, {Myung Hwan} and Philippe L{\'e}vy and Atsushi Masamune and George Webster and Tooru Shimosegawa",
year = "2016",
month = "9",
day = "7",
doi = "10.1016/j.pan.2016.12.003",
language = "English (US)",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - International consensus for the treatment of autoimmune pancreatitis

AU - Okazaki, Kazuichi

AU - Chari, Suresh T

AU - Frulloni, Luca

AU - Lerch, Markus M.

AU - Kamisawa, Terumi

AU - Kawa, Shigeyuki

AU - Kim, Myung Hwan

AU - Lévy, Philippe

AU - Masamune, Atsushi

AU - Webster, George

AU - Shimosegawa, Tooru

PY - 2016/9/7

Y1 - 2016/9/7

N2 - Background and aims: The International Consensus Diagnostic Criteria (ICDC) for AIP has proposed two distinctive type of AIP, type 1 and type 2, and enabled us first to differentiate two types of AIP each other. By initial steroid treatment for induction of remission, remission can be successfully induced in almost all subjects with type 1 and type 2 AIP. As relapse rate in type 1 AIP is significantly higher than in type 2 AIP, there has been ongoing debate on how to treat effectively relapse of type 1 AIP. Methods: By a modified Delphi approach, a panel of international experts has proposed an international consensus on the treatment of AIP after intense discussion and deliberation during an international consensus symposium of the International Association of Pancreatology (IAP) 2016. Results: Individual statements for nine clinical questions with recommendation levels and the therapeutic strategy have been proposed. Conclusion: The recommendations are based on the available evidence, and eastern and western experts' opinions to find standard treatment of AIP worldwide. These recommendations can be tailored according to the local expertise and context in the management of individual patients.

AB - Background and aims: The International Consensus Diagnostic Criteria (ICDC) for AIP has proposed two distinctive type of AIP, type 1 and type 2, and enabled us first to differentiate two types of AIP each other. By initial steroid treatment for induction of remission, remission can be successfully induced in almost all subjects with type 1 and type 2 AIP. As relapse rate in type 1 AIP is significantly higher than in type 2 AIP, there has been ongoing debate on how to treat effectively relapse of type 1 AIP. Methods: By a modified Delphi approach, a panel of international experts has proposed an international consensus on the treatment of AIP after intense discussion and deliberation during an international consensus symposium of the International Association of Pancreatology (IAP) 2016. Results: Individual statements for nine clinical questions with recommendation levels and the therapeutic strategy have been proposed. Conclusion: The recommendations are based on the available evidence, and eastern and western experts' opinions to find standard treatment of AIP worldwide. These recommendations can be tailored according to the local expertise and context in the management of individual patients.

KW - Autoimmune pancreatitis

KW - Immunomodulatory

KW - Rituximab

KW - Steroid

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85008152751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008152751&partnerID=8YFLogxK

U2 - 10.1016/j.pan.2016.12.003

DO - 10.1016/j.pan.2016.12.003

M3 - Article

C2 - 28027896

AN - SCOPUS:85008152751

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

ER -